Follow Us:

This activity is designed to meet the educational needs of medical oncologists, urologic oncologists, nurse practitioners, PAs, nurses and other healthcare professionals who manage patients with mCRPC.
A focused online module that examines the mechanistic rationale, discusses the latest evidence, and explores the potential role of PARP inhibitor-based combination therapy in the treatment of patients with advanced prostate cancer.
Upon completion of this activity, participants should be better able to: